Aerovate Therapeutics (JBIO) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $6.57 to $7.26
• 50-Day Range: N/A
• 52-Week Range: $6.57 to $884.97
• Volume: 240,117 shs
• Average Volume: 93,846 shs
• Market Capitalization: $5.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

JBIO Stock Analysis - Frequently Asked Questions

How have JBIO shares performed this year?

Aerovate Therapeutics' stock was trading at $7.06 at the start of the year. Since then, JBIO shares have decreased by 4.2% and is now trading at $6.76.
View the best growth stocks for 2025 here.

How do I buy shares of Aerovate Therapeutics?

Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: N/A
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 841,000
• Free Float: N/A
• Market Cap: $5.69 million
• Optionable: N/A
• Beta: 0.93